Biophytis Advances Partnership Strategy in Obesity Sector

Biophytis SA, a Paris and Cambridge-based biotechnology firm, announced its new initiative for expanding partnerships focused on obesity treatments. Aimed at advancing their drug candidate, BIO101, which is in phase 2 clinical development, the company is actively seeking regional and global pharmaceutical partners to co-develop and commercialize the treatment.

The strategic move involves licensing out BIO101, which is geared to work in tandem with GLP-1 receptor agonists. This drug addresses obesity by enhancing its clinical effectiveness through potential partnerships. This initiative is supported by a robust action plan that includes participating in leading pharma events, such as the upcoming BIO US conference in San Diego.

CEO Stanislas Veillet highlighted the critical nature of addressing the growing obesity challenge in key markets like the USA, China, and Brazil. He emphasized the importance of collaboration with leading innovators in healthcare to meet the needs of obese patients globally. The company underlines trust, expertise, performance, and ambition as fundamental values guiding their partnership approach.